KRAS and colorectal carcinoma: Furthermore, the combinatorial perturbations to KRAS and CTNNB1, as well as KRAS and TGFBR2, enhanced the causal impact on the EMT pathway compared to their single perturbations, suggesting potential combination therapies for the specific CMS4 subtype of CRC.